Proliferative diabetic retinopathy
Conditions
Interventions
Experimental group:Immediately after PPV, a single intravitreal injection of ranibizumab (0.5mg/0.05mL) was used as usual after PPV
Control group:Immediate ranibizumab injection is not given after PPV, and conventional treatment after PPV is used
Sponsors
Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with type 2 diabetes; 2. The eye with poor baseline best corrected visual acuity (BCVA) in both eyes at the time of the patient's visit was taken as the target eye, and the target eye was in line with the diagnosis of proliferative diabetic retinopathy. 3. The target eye has one or more of the following conditions that meet the surgical indications for vitrectomy (PPV) : non-absorbable vitreous hemorrhage, fibroproliferative membrane of PDR, preretinal hemorrhage, retinal traction and tractional retinal detachment, tractional rhegmatogenous retinal detachment, vitreous hemorrhage combined with cataract, vitreous hemorrhage combined with iris neovascularization, etc. 4. The patient's blood glucose and blood pressure were well controlled before the operation. 5. The subjects and their family members understand and agree to participate in this study, and have signed the informed consent; 6. Good compliance and high cooperation.
Exclusion criteria
Exclusion criteria: 1. In addition to intravitreal injection of ranibizumab or aflibercept, any other laser, surgical or injection treatments have been received within the past 3 months; 2. Known allergy or intolerance to anti-VEGF drugs; 3. Symptomatic visual loss caused by PDR more than 1 year; 4. Patients with various types of glaucoma or macular degeneration; 5. Thromboembolic event (including myocardial infarction or cerebrovascular event) in the past 6 months; 6. Known coagulation abnormalities or use of anticoagulants within 3 days;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cumulative incidence of major complications within 3 months after treatment: vitreous hemorrhage, choroidal detachment, macular epiretinal membrane, macular edema, anterior chamber reaction, iris adhe;Best corrected visual acuity (BCVA) at 3 months after treatment: the change in BCVA of the target eye from baseline to 3 months after treatment.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence and severity of adverse events;Central macular thickness measured by optical coherence tomography (OCT);Visual acuity was corrected at 1 week and 1 month after treatment;Proportion of patients requiring secondary treatment; | — |
Countries
China
Contacts
Public ContactXian Zhang
Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology
Outcome results
None listed